COOPER COMPANIES, INC. (COO)

The Cooper Companies, Inc. is a global medical device company headquartered in San Ramon, California. It sells products in over 130 countries and operates through two business segments, CooperVision and CooperSurgical, which provide products and services in the fields of vision, fertility and women's health.

CooperVision develops, manufactures and markets single-use, two-week and monthly soft contact lenses, including spherical, toric and multifocal lenses made with advanced materials such as silicone hydrogel. Its brands include Biofinity (its highest-grossing product, a monthly lens), MyDay and clariti 1 day (single-use silicone hydrogel), Avaira Vitality (two-week), and Proclear and Biomedics (single-use hydrogel). It also offers myopia management products, notably the internally developed MiSight 1 day lens, approved by the FDA in November 2019 for slowing myopia progression in children aged 8-12, and later approved in China and Japan, as well as ortho-k and scleral lenses. CooperSurgical offers more than 600 products and services in fertility and women's health. These include surgical products, contraception (including the hormone-free Paragard IUD, sold only in the U.S.), labor and delivery products, and cord blood and cord tissue storage. Its fertility portfolio covers IVF media, micro-tools and lab equipment, donor eggs and sperm, cryostorage and genomic services including genetic testing.

CooperVision serves contact lens wearers through eye care practitioners and key accounts such as optical chains, global retailers, buying groups and mass merchandisers, across the Americas, EMEA and Asia Pacific. CooperSurgical's customers include OB/GYN and medical offices, hospitals, ambulatory surgery centers and fertility clinics, as well as direct-to-consumer channels. Key accounts include large group practices, integrated delivery networks, buying groups and fertility clinic networks. The company notes consolidation of practices and clinics, rising infertility rates, increasing maternal age and growth in office-based procedures as market trends.

CooperVision's major manufacturing and distribution facilities are in Belgium, Costa Rica, Hungary, Puerto Rico, the United Kingdom and the United States. CooperSurgical's manufacturing, cryostorage and distribution sites are in Costa Rica, the Netherlands, the United Kingdom and the United States, and it operates a CLIA-certified genetic testing laboratory in New Jersey. CooperVision competes mainly with Johnson & Johnson Vision Care, Alcon and Bausch + Lomb. CooperSurgical competes with companies such as Vitrolife Group, Fairfax Cryobank, Johnson & Johnson, Baxter, Medtronic, Hologic, ViaCord (Revvity), Bayer, AbbVie and Organon. The company employs about 500 people in research and development, and its products are subject to extensive FDA and international regulation.